EFPIA anti-counterfeiting pilot success could see industry recognise parallel traders as part of supply chain
This article was originally published in SRA
Mass serialisation is a viable way of strengthening the supply chain and protecting against counterfeit medicines, a pilot launched by the European Federation of Pharmaceutical Industries and Associations has shown1. Furthermore, roll-out of such a verification system could prompt industry to recognise parallel traders as part of the supply chain.
You may also be interested in...
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.